CA2917603C - Methods for increasing forced expiratory volume in asthmatics using benralizumab - Google Patents
Methods for increasing forced expiratory volume in asthmatics using benralizumab Download PDFInfo
- Publication number
- CA2917603C CA2917603C CA2917603A CA2917603A CA2917603C CA 2917603 C CA2917603 C CA 2917603C CA 2917603 A CA2917603 A CA 2917603A CA 2917603 A CA2917603 A CA 2917603A CA 2917603 C CA2917603 C CA 2917603C
- Authority
- CA
- Canada
- Prior art keywords
- benralizumab
- antigen
- binding fragment
- fevi
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229950000321 benralizumab Drugs 0.000 title claims abstract description 148
- 208000006673 asthma Diseases 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title abstract description 54
- 239000012634 fragment Substances 0.000 claims abstract description 90
- 239000000427 antigen Substances 0.000 claims abstract description 89
- 102000036639 antigens Human genes 0.000 claims abstract description 89
- 108091007433 antigens Proteins 0.000 claims abstract description 89
- 210000003979 eosinophil Anatomy 0.000 claims description 50
- 229940125369 inhaled corticosteroids Drugs 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000005713 exacerbation Effects 0.000 claims description 27
- 229940125389 long-acting beta agonist Drugs 0.000 claims description 11
- 239000003246 corticosteroid Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 1
- 229940068196 placebo Drugs 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 238000012216 screening Methods 0.000 description 20
- 238000013125 spirometry Methods 0.000 description 17
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 16
- 229960002052 salbutamol Drugs 0.000 description 16
- 238000005259 measurement Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000002327 eosinophilic effect Effects 0.000 description 8
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 7
- 102100034217 Non-secretory ribonuclease Human genes 0.000 description 7
- 229960004436 budesonide Drugs 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
- 229960002329 methacholine Drugs 0.000 description 7
- 229940124624 oral corticosteroid Drugs 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 229940124630 bronchodilator Drugs 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 4
- 230000009798 acute exacerbation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000037874 Asthma exacerbation Diseases 0.000 description 3
- 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 3
- 206010014950 Eosinophilia Diseases 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- 208000024716 acute asthma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004017 salmeterol Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 2
- 238000013313 FeNO test Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229940074409 trehalose dihydrate Drugs 0.000 description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010014940 Eosinopenia Diseases 0.000 description 1
- 101001080292 Homo sapiens Iron-sulfur cluster co-chaperone protein HscB Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
- 102100027530 Iron-sulfur cluster co-chaperone protein HscB Human genes 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000005591 NIMA-Interacting Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000024747 near-fatal asthma Diseases 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 | |
| US61/864,948 | 2013-08-12 | ||
| PCT/US2014/050119 WO2015023507A2 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2917603A1 CA2917603A1 (en) | 2015-02-19 |
| CA2917603C true CA2917603C (en) | 2023-05-16 |
Family
ID=52448838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2917603A Active CA2917603C (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (enExample) |
| EP (4) | EP3520811B1 (enExample) |
| JP (4) | JP6746496B2 (enExample) |
| KR (1) | KR102337599B1 (enExample) |
| CN (2) | CN111588849A (enExample) |
| AU (2) | AU2014306959B2 (enExample) |
| BR (1) | BR112016002317A8 (enExample) |
| CA (1) | CA2917603C (enExample) |
| CY (2) | CY1122033T1 (enExample) |
| DK (2) | DK3033104T3 (enExample) |
| ES (2) | ES2866426T3 (enExample) |
| HK (1) | HK1222559A1 (enExample) |
| HR (2) | HRP20190920T1 (enExample) |
| HU (2) | HUE043497T2 (enExample) |
| LT (2) | LT3033104T (enExample) |
| ME (1) | ME03403B (enExample) |
| MX (2) | MX381102B (enExample) |
| PL (2) | PL3033104T3 (enExample) |
| PT (2) | PT3033104T (enExample) |
| RS (2) | RS58711B1 (enExample) |
| RU (1) | RU2703568C2 (enExample) |
| SG (1) | SG11201600483QA (enExample) |
| SI (2) | SI3033104T1 (enExample) |
| SM (2) | SMT202100152T1 (enExample) |
| TR (1) | TR201907907T4 (enExample) |
| WO (1) | WO2015023507A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023504A1 (en) | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| MX368474B (es) | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| CA2402477A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20070148170A1 (en) | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| DK3072525T3 (en) * | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| KR101615474B1 (ko) * | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| US20140328839A1 (en) | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| MX368474B (es) | 2013-08-12 | 2019-10-04 | Astrazeneca Ab | Uso de benralizumab para mejorar síntomas de asma. |
| WO2015023504A1 (en) | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
-
2014
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active Active
- 2014-08-07 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en not_active Ceased
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 SM SM20210152T patent/SMT202100152T1/it unknown
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en not_active Withdrawn
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 SM SM20190311T patent/SMT201900311T1/it unknown
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 EP EP25150773.7A patent/EP4579236A3/en active Pending
- 2014-08-07 MX MX2016001384A patent/MX381102B/es unknown
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
-
2019
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108997A patent/JP2024129140A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| CA2917603C (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| AU2020202564A1 (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40058739A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40064505A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225300B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40013807B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| HK1225303B (en) | Methods for improving asthma symptoms using benralizumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190806 |
|
| EEER | Examination request |
Effective date: 20190806 |
|
| EEER | Examination request |
Effective date: 20190806 |
|
| EEER | Examination request |
Effective date: 20190806 |
|
| EEER | Examination request |
Effective date: 20190806 |
|
| EEER | Examination request |
Effective date: 20190806 |